

## MODERN VIEW ON THE USE OF MOXIFLOXACIN IN TREATMENT OF PULMONARY TUBERCULOSIS

**L. I. Grechanik**

*Abstract*

The prevalence of tuberculosis in Ukraine determines the need to increase efficiency and reduce the terms of treatment. The development of new effective anti-tuberculosis drugs and treatment regimens, being a global necessity, can significantly reduce the treatment time. Among the latest generation fluoroquinolones, moxifloxacin is considered the most promising for tuberculosis management. A number of studies shows that moxifloxacin can be administered for reduction of terms of treatment in patients with resistance to standard chemotherapy drugs. However finally it has not been approved: further research is needed. In recently offered combinations moxifloxacin may occupy a key position in terms of reducing the duration of treatment both in susceptible and difficult-to-treat cases of tuberculosis.

**Key words:** tuberculosis, chemotherapy, fluoroquinolones, moxifloxacin.

**Ukr. Pulmonol. J. 2016; 4:64–69.**

*Leonid I. Grechanik*

*National Institute of Phthysiology and pulmonology*

*named after F. G. Yanovskyi NAMS of Ukraine";*

*NMMCC "GVKG"*

*The resident clinic tuberculosis*

*10, M. Amosova str., Kyiv, 03680,*

*Tel.: 38 044 521-85-05, grechanik-leonid@ukr.net*

---